Nanoparticles from renewable polymers

Wurm, Frederik R.; Weiss, Clemens K.

doi:10.3389/fchem.2014.00049

Cited by 85 publications

(56 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The polymeric nanoparticles have been shown to alter and improve the pharmacokinetic and pharmacodynamic properties of various bioactive molecules. The above mentioned properties of polymeric nanoparticles can be applied to overcome some of the limitations in traditional drug delivery approaches [211]. Polymeric nanoparticles have been used in vivo to protect the drug in the systemic circulation, and to deliver the drug at a controlled rate to the site of action while minimizes undesirable side effects [212].…”

Section: Nanotechnology Based Approaches To Deliver Rnai Based Commentioning

confidence: 99%

Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances

Gandhi

Tekade

Chougule

2014

Journal of Controlled Release

328

270

View full text Add to dashboard Cite

Chemotherapeutic agents have certain limitations when it comes to treating cancer, the most important being severe side effects along with multidrug resistance developed against them. Tumor cells exhibits drug resistance due to activation of various cellular level processes viz. activation of drug efflux pumps, anti-apoptotic defense mechanisms etc. Currently, RNA interference (RNAi) based therapeutic approaches are under vibrant scrutinization to seek cancer cure. Especially small interfering RNA (siRNA) and micro RNA (miRNA), are able to knock down the carcinogenic genes by targeting the mRNA expression, which underlies the uniqueness of this therapeutic approach. Recent research focus in the regime of cancer therapy involves the engagement of targeted delivery of siRNA/miRNA in combinations with other therapeutic agents (such as gene, DNA or chemotherapeutic drug) for targeting permeability glycoprotein (P-gp), Multidrug resistant protein 1(MRP-1), B-cell lymphoma (BCL-2) and other targets that are mainly responsible for resistance in cancer therapy. RNAi-chemotherapeutic drug combinations have also been found to be effective against different molecular targets as well and can increase the sensitization of cancer cells to therapy several folds. However, due to stability issues associated with siRNA/miRNA suitable protective carrier is needed and nanotechnology based approaches have been widely explored to overcome these drawbacks. Furthermore, it has been univocally advocated that the co-delivery of siRNA/miRNA with other chemodrugs significantly enhances their capability to overcome cancer resistance compared to naked counterparts. The objective of this article is to review recent nanocarrier based approaches adopted for the delivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat cancer.

show abstract

Section: Nanotechnology Based Approaches To Deliver Rnai Based Commentioning

confidence: 99%

Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances

Gandhi

Tekade

Chougule

2014

Journal of Controlled Release

328

270

View full text Add to dashboard Cite

show abstract

“…Both Kubek et al and Veronesi et al used anticonvulsant thyrotropin‐releasing hormone polylactide NPs (108 nm) to treat electrode‐induced seizures/epilepsy in rats, demonstrating that NPs crossed the BBB and increased the seizure threshold . Natural polymeric NPs, like chitosan, gelatin, or alginate, can provide improved delivery and sustained drug release, are readily available on a large scale, and are low cost . Haque et al used alginate NPs (167 nm, +23 mV) loaded with the antidepressant venlafaxine in a rat depression model, which improved neurobehavioral function compared to free‐drug treated rats.…”

Section: Nanoparticle Administration Routes To Overcome Barriers For mentioning

confidence: 99%

“…208,209 Natural polymeric NPs, like chitosan, gelatin, or alginate, can provide improved delivery and sustained drug release, are readily available on a large scale, and are low cost. 210 Haque et al used alginate NPs (167 nm, +23 mV) loaded with the antidepressant venlafaxine in a rat depression model, 211 which improved neurobehavioral function compared to free-drug treated rats. Singh et al conducted a similar study using selegiline hydrochloride, another antidepressant, encapsulated in thiolated chitosan NPs (215 nm, +17 mV), which improved forced swimming and decreased immobility time after tail suspension compared to control animals.…”

Section: Intranasal Deliverymentioning

confidence: 99%

Systems‐level thinking for nanoparticle‐mediated therapeutic delivery to neurological diseases

Curtis

Zhang

Liao

et al. 2016

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Neurological diseases account for 13% of the global burden of disease. As a result, treating these diseases costs $750 billion a year. Nanotechnology, which consists of small (~1-100 nm) but highly tailorable platforms, can provide significant opportunities for improving therapeutic delivery to the brain. Nanoparticles can increase drug solubility, overcome the blood-brain and brain penetration barriers, and provide timed release of a drug at a site of interest. Many researchers have successfully used nanotechnology to overcome individual barriers to therapeutic delivery to the brain, yet no platform has translated into a standard of care for any neurological disease. The challenge in translating nanotechnology platforms into clinical use for patients with neurological disease necessitates a new approach to: (1) collect information from the fields associated with understanding and treating brain diseases and (2) apply that information using scalable technologies in a clinically-relevant way. This approach requires systems-level thinking to integrate an understanding of biological barriers to therapeutic intervention in the brain with the engineering of nanoparticle material properties to overcome those barriers. To demonstrate how a systems perspective can tackle the challenge of treating neurological diseases using nanotechnology, this review will first present physiological barriers to drug delivery in the brain and common neurological disease hallmarks that influence these barriers. We will then analyze the design of nanotechnology platforms in preclinical in vivo efficacy studies for treatment of neurological disease, and map concepts for the interaction of nanoparticle physicochemical properties and pathophysiological hallmarks in the brain. WIREs Nanomed Nanobiotechnol 2017, 9:e1422. doi: 10.1002/wnan.1422 For further resources related to this article, please visit the WIREs website.

show abstract

“…These are (i) the choice of solvent medium used for the synthesis, (ii) use of environmentally benign reducing agent and (iii) the choice of non-toxic material as stabilizing agent. The use of environmentally benign materials for the synthesis of metal nanoparticles provides numerous benefits ranging from biocompatibility, renewable feedstocks, cost-effectiveness, waste prevention, amenable scale-up, synthetic steps reduction, use of safer solvents and increase of energy efficiency to eco-friendliness [15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Biopolymer-mediated Green Synthesis of Noble Metal Nanostructures

Fakayode¹,

Oladipo²,

Oluwafemi³

et al. 2016

Recent Advances in Biopolymers

View full text Add to dashboard Cite

Polymer-coated noble metal nanoparticles are currently of particular interest to investigators in the fields of nanobiomedicine and fundamental biomaterials. These materials not only exhibit imaging properties in response to stimuli but also efficiently deliver various drugs and therapeutic genes. Even though a large number of polymer-coated noble metal nanoparticles have been fabricated over the past decade, most of these materials still present some challenges emanating from their synthesis. The metal nanoparticles when encapsulated in a polymer and taken up by human cells might show a lower degree of toxicity however, the degree of toxicity for some of the starting materials and precursors has raised serious concerns. Hence, there is a need to implement the principle of green chemistry in the synthesis of nanomaterials. The use of environmentally benign materials for the synthesis of metal nanoparticles provides numerous benefits ranging from biocompatibility, availability, cost-effectiveness, amenable scale-up to eco-friendliness. The biopolymer-based nanovehicles have been found to be more suitable in the field of nanotechnology owing to their high reproducibility, ease of manufacture, functional modification and safety they are not carcinogenic . Unlike synthetic polymers where the raw material can be derived from petrochemicals or chemical industrial processes, biopolymers are produced from renewable resources such as plant and/or living organism. They are degradable by natural processes down to elemental entities that can be resorbed in the environment. Furthermore, they can also be modified to serve a particular purpose which explains the myriad of their potential applications. The macromolecular chain of these biopolymers possesses a large number of hydroxyl groups which can easily complex with metal ions. "dditionally, these biopolymers also contain supramolecular structures that can lead to new functionalities of their composites with metal and semiconductor nanoparticles. In this chapter, a comprehensive discussion on different biopolymers, green synthesis of noble metal nanostructures, mechanisms, characterization and application in various fields is presented.

show abstract

Nanoparticles from renewable polymers

Cited by 85 publications

References 164 publications

Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances

Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances

Systems‐level thinking for nanoparticle‐mediated therapeutic delivery to neurological diseases

Biopolymer-mediated Green Synthesis of Noble Metal Nanostructures

Contact Info

Product

Resources

About